JP2008502669A - 炎症の治療に有用なインドール類 - Google Patents
炎症の治療に有用なインドール類 Download PDFInfo
- Publication number
- JP2008502669A JP2008502669A JP2007516043A JP2007516043A JP2008502669A JP 2008502669 A JP2008502669 A JP 2008502669A JP 2007516043 A JP2007516043 A JP 2007516043A JP 2007516043 A JP2007516043 A JP 2007516043A JP 2008502669 A JP2008502669 A JP 2008502669A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- indole
- substituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 27
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 27
- 150000002475 indoles Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 313
- 102100033076 Prostaglandin E synthase Human genes 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 24
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 230000005764 inhibitory process Effects 0.000 claims abstract description 12
- -1 methylenedioxy, difluoromethylenedioxy Chemical group 0.000 claims description 253
- 238000000034 method Methods 0.000 claims description 88
- 125000005843 halogen group Chemical group 0.000 claims description 70
- 125000001424 substituent group Chemical group 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000004122 cyclic group Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 150000002431 hydrogen Chemical group 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 claims description 8
- 101710187011 Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010037660 Pyrexia Diseases 0.000 claims description 5
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 claims description 4
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- MJPPGVVIDGQOQT-UHFFFAOYSA-N 2-bromo-5-(2-bromo-2-nitroethenyl)furan Chemical compound [O-][N+](=O)C(Br)=CC1=CC=C(Br)O1 MJPPGVVIDGQOQT-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- LCIYFINKFGDAHD-UHFFFAOYSA-N azepane;3-nitrobenzoic acid Chemical compound C1CCCNCC1.OC(=O)C1=CC=CC([N+]([O-])=O)=C1 LCIYFINKFGDAHD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000003195 fascia Anatomy 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 239000011734 sodium Substances 0.000 description 32
- 239000012267 brine Substances 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 235000019439 ethyl acetate Nutrition 0.000 description 27
- 230000007062 hydrolysis Effects 0.000 description 22
- 238000006460 hydrolysis reaction Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000010931 ester hydrolysis Methods 0.000 description 19
- 239000000284 extract Substances 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 125000001153 fluoro group Chemical group F* 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- CJUHQADBFQRIMC-UHFFFAOYSA-N (4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1 CJUHQADBFQRIMC-UHFFFAOYSA-N 0.000 description 10
- QQXQAEWRSVZPJM-UHFFFAOYSA-N ethyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC2=C1 QQXQAEWRSVZPJM-UHFFFAOYSA-N 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 7
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 150000002148 esters Chemical group 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 7
- GSKMWMFOQQBVMI-UHFFFAOYSA-N 2-bromo-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)N=C1 GSKMWMFOQQBVMI-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000011097 chromatography purification Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- WWHADOQRDLXPGB-UHFFFAOYSA-N ethyl 5-bromo-3-chloro-1-(4-cyclopentyloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C2=CC(Br)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 WWHADOQRDLXPGB-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- IZOOGQYKHWNGOK-UHFFFAOYSA-N (4-cyclopropyloxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1CC1 IZOOGQYKHWNGOK-UHFFFAOYSA-N 0.000 description 4
- MPAOOLLBWUEXOM-UHFFFAOYSA-N 1-bromo-4-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(Br)C=C1 MPAOOLLBWUEXOM-UHFFFAOYSA-N 0.000 description 4
- YZJKABHVNULQLT-UHFFFAOYSA-N 3-chloro-1-(4-propan-2-yloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3N=CC(=CC=3)C(F)(F)F)C=C2C(Cl)=C1C(O)=O YZJKABHVNULQLT-UHFFFAOYSA-N 0.000 description 4
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 4
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- NKPBWBIYQVCQDU-UHFFFAOYSA-N ethyl 3-chloro-1-(4-propan-2-yloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C1=CC=C(OC(C)C)C=C1 NKPBWBIYQVCQDU-UHFFFAOYSA-N 0.000 description 4
- LWRLKENDQISGEU-UHFFFAOYSA-N ethyl 5-bromo-1h-indole-2-carboxylate Chemical compound BrC1=CC=C2NC(C(=O)OCC)=CC2=C1 LWRLKENDQISGEU-UHFFFAOYSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 4
- 150000002617 leukotrienes Chemical class 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- FSZRSTNRZUIEMA-UHFFFAOYSA-N 5-bromo-2-propan-2-yloxypyridine Chemical compound CC(C)OC1=CC=C(Br)C=N1 FSZRSTNRZUIEMA-UHFFFAOYSA-N 0.000 description 3
- UEGOCPHAEVCTIC-UHFFFAOYSA-N 6-bromo-n-cyclopentylpyridin-3-amine Chemical compound C1=NC(Br)=CC=C1NC1CCCC1 UEGOCPHAEVCTIC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101001135391 Homo sapiens Prostaglandin E synthase Proteins 0.000 description 3
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 150000001923 cyclic compounds Chemical class 0.000 description 3
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- AZIQBCMGQLILDZ-UHFFFAOYSA-N ethyl 1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3C=CC(OC(C)C)=CC=3)=CC=C2N1C1=CC=C(OC(C)C)C=C1 AZIQBCMGQLILDZ-UHFFFAOYSA-N 0.000 description 3
- WWEVALYMKTZGTR-UHFFFAOYSA-N ethyl 3-chloro-1-(4-propan-2-yloxyphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-2-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C1=CC=C(OC(C)C)C=C1 WWEVALYMKTZGTR-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- 102000047789 human PTGES Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 3
- DKYRKAIKWFHQHM-UHFFFAOYSA-N (3,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC(Cl)=C1 DKYRKAIKWFHQHM-UHFFFAOYSA-N 0.000 description 2
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 2
- KNQVRFYNQWNYPU-UHFFFAOYSA-N (4-cyclohexylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1CCCCC1 KNQVRFYNQWNYPU-UHFFFAOYSA-N 0.000 description 2
- SHFUCWRBJNBYAZ-UHFFFAOYSA-N (5-chloropyridin-2-yl) trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=C(Cl)C=N1 SHFUCWRBJNBYAZ-UHFFFAOYSA-N 0.000 description 2
- SGEOBUJTURUUJE-UHFFFAOYSA-N (6-propan-2-yloxypyridin-3-yl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=N1 SGEOBUJTURUUJE-UHFFFAOYSA-N 0.000 description 2
- 0 *c1cc(c(*)c(*)c(*)c2*)c2[n]1 Chemical compound *c1cc(c(*)c(*)c(*)c2*)c2[n]1 0.000 description 2
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- JKUATHYJTCJWTE-UHFFFAOYSA-N 1-(4-cyclopropyloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C(C=C1)=CC=C1OC1CC1 JKUATHYJTCJWTE-UHFFFAOYSA-N 0.000 description 2
- NDHWJPPQWXMPAY-UHFFFAOYSA-N 1-(4-propan-2-yloxyphenyl)-5-(6-propan-2-yloxypyridin-3-yl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3C=NC(OC(C)C)=CC=3)C=C2C=C1C(O)=O NDHWJPPQWXMPAY-UHFFFAOYSA-N 0.000 description 2
- JDZJFPBEYZAJQR-UHFFFAOYSA-N 1-(4-propan-2-yloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3N=CC(=CC=3)C(F)(F)F)C=C2C=C1C(O)=O JDZJFPBEYZAJQR-UHFFFAOYSA-N 0.000 description 2
- YYDVIPOVAFWYRT-UHFFFAOYSA-N 1-(6-propan-2-yloxypyridin-3-yl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound C1=NC(OC(C)C)=CC=C1N1C2=CC=C(C=3N=CC(=CC=3)C(F)(F)F)C=C2C=C1C(O)=O YYDVIPOVAFWYRT-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- DTPRNRZMYZTZLG-UHFFFAOYSA-N 1-[2-(4-bromophenoxy)-2-methylpropyl]pyrrolidine Chemical compound C=1C=C(Br)C=CC=1OC(C)(C)CN1CCCC1 DTPRNRZMYZTZLG-UHFFFAOYSA-N 0.000 description 2
- OHFYZHBLYOTILN-UHFFFAOYSA-N 1-[4-(2-methylpropoxy)phenyl]-5-[4-(trifluoromethoxy)phenyl]indole-2-carboxylic acid Chemical compound C1=CC(OCC(C)C)=CC=C1N1C2=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C=C1C(O)=O OHFYZHBLYOTILN-UHFFFAOYSA-N 0.000 description 2
- DWMSXAAIGFYBGC-UHFFFAOYSA-N 1-bromo-4-cyclopentyloxybenzene Chemical compound C1=CC(Br)=CC=C1OC1CCCC1 DWMSXAAIGFYBGC-UHFFFAOYSA-N 0.000 description 2
- FOCLRODNGKLAOT-UHFFFAOYSA-N 1-bromo-4-cyclopropyloxybenzene Chemical compound C1=CC(Br)=CC=C1OC1CC1 FOCLRODNGKLAOT-UHFFFAOYSA-N 0.000 description 2
- PPNABDIAKJRGJI-UHFFFAOYSA-N 1-bromo-4-ethenoxybenzene Chemical compound BrC1=CC=C(OC=C)C=C1 PPNABDIAKJRGJI-UHFFFAOYSA-N 0.000 description 2
- KRDRSIKTOZUDDD-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methyl-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1CCCN1C(=O)C(C)(C)OC1=CC=C(Br)C=C1 KRDRSIKTOZUDDD-UHFFFAOYSA-N 0.000 description 2
- NYCCCTCANQPTAF-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methylpropan-1-ol Chemical compound OCC(C)(C)OC1=CC=C(Br)C=C1 NYCCCTCANQPTAF-UHFFFAOYSA-N 0.000 description 2
- XEGDEYNAWWGQFF-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methylpropanoyl chloride Chemical compound ClC(=O)C(C)(C)OC1=CC=C(Br)C=C1 XEGDEYNAWWGQFF-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- PYAMGTGZAKUPNN-UHFFFAOYSA-N 3-bromo-1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(C(O)=O)=C2Br)C=3C=CC(OC(C)C)=CC=3)C2=C1 PYAMGTGZAKUPNN-UHFFFAOYSA-N 0.000 description 2
- RZDXHAYCFXMJIQ-UHFFFAOYSA-N 3-chloro-1-(4-cyclopentyloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound OC(=O)C1=C(Cl)C2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 RZDXHAYCFXMJIQ-UHFFFAOYSA-N 0.000 description 2
- AFPWFERFWPIDGD-UHFFFAOYSA-N 3-chloro-1-(6-cyclopentyloxypyridin-3-yl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound OC(=O)C1=C(Cl)C2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C(C=N1)=CC=C1OC1CCCC1 AFPWFERFWPIDGD-UHFFFAOYSA-N 0.000 description 2
- FWHDPZOVTUHUAC-UHFFFAOYSA-N 3-chloro-5-(4-propan-2-yloxyphenyl)-1-(6-propan-2-yloxypyridin-3-yl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(C(O)=O)=C2Cl)C=3C=NC(OC(C)C)=CC=3)C2=C1 FWHDPZOVTUHUAC-UHFFFAOYSA-N 0.000 description 2
- NJCIDLMWSCKNKB-UHFFFAOYSA-N 3-chloro-5-(5-chloropyridin-2-yl)-1-(4-cyclopentyloxyphenyl)indole-2-carboxylic acid Chemical compound OC(=O)C1=C(Cl)C2=CC(C=3N=CC(Cl)=CC=3)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 NJCIDLMWSCKNKB-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QFPAXFIUYZUPGB-UHFFFAOYSA-N 4-acetamido-1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC(OC(C)C)=CC=3)C2=C1NC(C)=O QFPAXFIUYZUPGB-UHFFFAOYSA-N 0.000 description 2
- LWKUTAHECIJMDZ-UHFFFAOYSA-N 4-nitro-1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC(OC(C)C)=CC=3)C2=C1[N+]([O-])=O LWKUTAHECIJMDZ-UHFFFAOYSA-N 0.000 description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 2
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 2
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 2
- MDBUQJNWZJVKTC-UHFFFAOYSA-N 5-(4-carbamoylphenyl)-1-(4-cyclopropyloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC(OC4CC4)=CC=3)C2=C1 MDBUQJNWZJVKTC-UHFFFAOYSA-N 0.000 description 2
- KFPKWYRAVIJFPJ-UHFFFAOYSA-N 5-(4-cyclohexylphenyl)-1-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3C=CC(=CC=3)C3CCCCC3)C=C2C=C1C(O)=O KFPKWYRAVIJFPJ-UHFFFAOYSA-N 0.000 description 2
- XSWRFQKNOIAIEM-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-(4-cyclopentyloxy-3-nitrophenyl)indole-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=C(C(OC4CCCC4)=CC=3)[N+]([O-])=O)C2=C1 XSWRFQKNOIAIEM-UHFFFAOYSA-N 0.000 description 2
- MQRUMFHIBDDKBJ-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-(4-cyclopropyloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC(OC4CC4)=CC=3)C2=C1 MQRUMFHIBDDKBJ-UHFFFAOYSA-N 0.000 description 2
- GUMCVDVWBMLUSQ-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3C=CC(=CC=3)C(C)(C)C)C=C2C=C1C(O)=O GUMCVDVWBMLUSQ-UHFFFAOYSA-N 0.000 description 2
- GPXYNVMUXFRKLB-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-[4-(1-hydroxy-2-methylpropan-2-yl)oxyphenyl]indole-2-carboxylic acid Chemical compound C1=CC(OC(C)(CO)C)=CC=C1N1C2=CC=C(C=3C=CC(=CC=3)C(C)(C)C)C=C2C=C1C(O)=O GPXYNVMUXFRKLB-UHFFFAOYSA-N 0.000 description 2
- ILMAYQWSNVYWPQ-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-[4-(2-methyl-1-pyrrolidin-1-ylpropan-2-yl)oxyphenyl]indole-2-carboxylic acid Chemical compound C=1C=C(N2C3=CC=C(C=C3C=C2C(O)=O)C=2C=CC(=CC=2)C(C)(C)C)C=CC=1OC(C)(C)CN1CCCC1 ILMAYQWSNVYWPQ-UHFFFAOYSA-N 0.000 description 2
- PXZZRDWERCLLDF-UHFFFAOYSA-N 5-(5-bromopyrimidin-2-yl)-1-(4-cyclopentyloxyphenyl)indole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(C=3N=CC(Br)=CN=3)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 PXZZRDWERCLLDF-UHFFFAOYSA-N 0.000 description 2
- NDMZZQRNZFWMEZ-UHFFFAOYSA-N 5-bromo-1h-pyridin-2-one Chemical compound OC1=CC=C(Br)C=N1 NDMZZQRNZFWMEZ-UHFFFAOYSA-N 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 101000628796 Homo sapiens Microsomal glutathione S-transferase 2 Proteins 0.000 description 2
- 101000628785 Homo sapiens Microsomal glutathione S-transferase 3 Proteins 0.000 description 2
- 102000042256 MAPEG family Human genes 0.000 description 2
- 108091077604 MAPEG family Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102100026741 Microsomal glutathione S-transferase 1 Human genes 0.000 description 2
- 102100026723 Microsomal glutathione S-transferase 2 Human genes 0.000 description 2
- 102100026722 Microsomal glutathione S-transferase 3 Human genes 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 230000003435 bronchoconstrictive effect Effects 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- YOOKYIPLSLPRTC-VMPITWQZSA-N ethyl (e)-3-(4-bromophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(Br)C=C1 YOOKYIPLSLPRTC-VMPITWQZSA-N 0.000 description 2
- XRZQJAWKMKDWEI-UHFFFAOYSA-N ethyl 1-(4-propan-2-yloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C1=CC=C(OC(C)C)C=C1 XRZQJAWKMKDWEI-UHFFFAOYSA-N 0.000 description 2
- GZOSJLUJZUJLTH-UHFFFAOYSA-N ethyl 1-(6-propan-2-yloxypyridin-3-yl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C1=CC=C(OC(C)C)N=C1 GZOSJLUJZUJLTH-UHFFFAOYSA-N 0.000 description 2
- JNCKYKBRYKAGMT-UHFFFAOYSA-N ethyl 3-chloro-1-(4-cyclopentyloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 JNCKYKBRYKAGMT-UHFFFAOYSA-N 0.000 description 2
- NWLQRRLZRBTEFS-UHFFFAOYSA-N ethyl 4-nitro-1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=C([N+]([O-])=O)C(C=3C=CC(OC(C)C)=CC=3)=CC=C2N1C1=CC=C(OC(C)C)C=C1 NWLQRRLZRBTEFS-UHFFFAOYSA-N 0.000 description 2
- XSFDWLBILDIZRX-UHFFFAOYSA-N ethyl 5-(4-propan-2-yloxyphenyl)-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C1=CC=C(OC(C)C)C=C1 XSFDWLBILDIZRX-UHFFFAOYSA-N 0.000 description 2
- JTPLCTLEILYUGB-UHFFFAOYSA-N ethyl 5-(4-tert-butylphenyl)-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C1=CC=C(C(C)(C)C)C=C1 JTPLCTLEILYUGB-UHFFFAOYSA-N 0.000 description 2
- XDRKEIJQBUBZNL-UHFFFAOYSA-N ethyl 5-bromo-3-chloro-1-(4-propan-2-yloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C2=CC(Br)=CC=C2N1C1=CC=C(OC(C)C)C=C1 XDRKEIJQBUBZNL-UHFFFAOYSA-N 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 108010074917 microsomal glutathione S-transferase-I Proteins 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- DITGUYGKQDIRGY-UHFFFAOYSA-M sodium;3-chloro-5-(4-cyclohexylphenyl)-1-[5-(cyclopentylamino)pyridin-2-yl]indole-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1=C(Cl)C2=CC(C=3C=CC(=CC=3)C3CCCCC3)=CC=C2N1C(N=C1)=CC=C1NC1CCCC1 DITGUYGKQDIRGY-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- AAMPOFTVRYFQCX-UHFFFAOYSA-N (4-cyclopentyloxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1CCCC1 AAMPOFTVRYFQCX-UHFFFAOYSA-N 0.000 description 1
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 1
- YJFPPRCWIADVCZ-UHFFFAOYSA-N (5-bromopyridin-2-yl) trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=C(Br)C=N1 YJFPPRCWIADVCZ-UHFFFAOYSA-N 0.000 description 1
- ILGIFDGNOCWNDV-UHFFFAOYSA-N (6-cyclopentyloxypyridin-3-yl)boronic acid Chemical compound N1=CC(B(O)O)=CC=C1OC1CCCC1 ILGIFDGNOCWNDV-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- PYMFRAHISOXABD-UHFFFAOYSA-N 1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC(OC(C)C)=CC=3)C2=C1 PYMFRAHISOXABD-UHFFFAOYSA-N 0.000 description 1
- HBXLSOCOZUGGPJ-UHFFFAOYSA-N 1,6-bis(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(C=C(C(O)=O)N2C=3C=CC(OC(C)C)=CC=3)C2=C1 HBXLSOCOZUGGPJ-UHFFFAOYSA-N 0.000 description 1
- CNSWJDUCUHERGH-UHFFFAOYSA-N 1-(4-ethoxyphenyl)-5-[4-(trifluoromethoxy)phenyl]indole-2-carboxylic acid Chemical compound C1=CC(OCC)=CC=C1N1C2=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C=C1C(O)=O CNSWJDUCUHERGH-UHFFFAOYSA-N 0.000 description 1
- DPYYIUXJVUYLFN-UHFFFAOYSA-N 1-(4-methoxyphenyl)-5-[4-(trifluoromethoxy)phenyl]indole-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1N1C2=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C=C1C(O)=O DPYYIUXJVUYLFN-UHFFFAOYSA-N 0.000 description 1
- XDKMDDOCVPNVMB-UHFFFAOYSA-N 1-bromo-3-methyl-2-nitrobenzene Chemical compound CC1=CC=CC(Br)=C1[N+]([O-])=O XDKMDDOCVPNVMB-UHFFFAOYSA-N 0.000 description 1
- SRGBSEMMGLSUMI-UHFFFAOYSA-N 1-bromo-4-(2-bromoethoxy)benzene Chemical compound BrCCOC1=CC=C(Br)C=C1 SRGBSEMMGLSUMI-UHFFFAOYSA-N 0.000 description 1
- WVUYYXUATWMVIT-UHFFFAOYSA-N 1-bromo-4-ethoxybenzene Chemical compound CCOC1=CC=C(Br)C=C1 WVUYYXUATWMVIT-UHFFFAOYSA-N 0.000 description 1
- ZDFBKZUDCQQKAC-UHFFFAOYSA-N 1-bromo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1 ZDFBKZUDCQQKAC-UHFFFAOYSA-N 0.000 description 1
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
- HNCYOUHRSLDDCE-UHFFFAOYSA-N 1-naphthalen-2-yl-5-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=C4C=CC=CC4=CC=3)C2=C1 HNCYOUHRSLDDCE-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- BDQVLRSNPCIHII-UHFFFAOYSA-N 1-phenyl-5-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC=CC=3)C2=C1 BDQVLRSNPCIHII-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- XLKOWBCIKDPOES-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methyl-1-(4-methylpiperazin-1-yl)propan-1-one;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C)(C)OC1=CC=C(Br)C=C1 XLKOWBCIKDPOES-UHFFFAOYSA-N 0.000 description 1
- NRDUHXQTTOHIJX-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Br)C=C1 NRDUHXQTTOHIJX-UHFFFAOYSA-N 0.000 description 1
- MUGDQJOJGQELPI-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methylpropanoyl chloride;methyl 2-(4-bromophenoxy)-2-methylpropanoate Chemical compound ClC(=O)C(C)(C)OC1=CC=C(Br)C=C1.COC(=O)C(C)(C)OC1=CC=C(Br)C=C1 MUGDQJOJGQELPI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- KMFMFXDNNBZACB-UHFFFAOYSA-N 2-chloro-5-(ethoxymethyl)pyridine Chemical compound CCOCC1=CC=C(Cl)N=C1 KMFMFXDNNBZACB-UHFFFAOYSA-N 0.000 description 1
- WVPHBBSAPVBUGZ-UHFFFAOYSA-N 2-chloro-5-propylpyrimidine Chemical compound CCCC1=CN=C(Cl)N=C1 WVPHBBSAPVBUGZ-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DBSLLYCGUZMBFQ-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-1-[4-(2-carboxypropan-2-yloxy)phenyl]indole-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C(C1=CC=CC=C11)=C(C(O)=O)N1C1=CC=C(OC(C)(C)C(O)=O)C=C1 DBSLLYCGUZMBFQ-UHFFFAOYSA-N 0.000 description 1
- UHQQSDAMSSVOQU-UHFFFAOYSA-N 3-bromo-2-propan-2-yloxypyridine Chemical compound CC(C)OC1=NC=CC=C1Br UHQQSDAMSSVOQU-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- MOFYHXPYYFVMFA-UHFFFAOYSA-N 3-chloro-1-(4-cyclopropyloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylic acid Chemical compound OC(=O)C1=C(Cl)C2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C(C=C1)=CC=C1OC1CC1 MOFYHXPYYFVMFA-UHFFFAOYSA-N 0.000 description 1
- LXEBZKKVGGEJKA-UHFFFAOYSA-N 3-chloro-5-(6-cyclopentyloxypyridin-3-yl)-1-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3C=NC(OC4CCCC4)=CC=3)C=C2C(Cl)=C1C(O)=O LXEBZKKVGGEJKA-UHFFFAOYSA-N 0.000 description 1
- JITNPQFEGRUGDZ-UHFFFAOYSA-N 3-chloro-5-[5-(cyclopentylamino)pyridin-2-yl]-1-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3N=CC(NC4CCCC4)=CC=3)C=C2C(Cl)=C1C(O)=O JITNPQFEGRUGDZ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DOFMKKALRMNHEH-UHFFFAOYSA-N 4-bromo-1-cyclopentyloxy-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1OC1CCCC1 DOFMKKALRMNHEH-UHFFFAOYSA-N 0.000 description 1
- BAIZWELNDHXHRW-UHFFFAOYSA-N 4-bromo-2-nitro-1-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(Br)C=C1[N+]([O-])=O BAIZWELNDHXHRW-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- XOKDXPVXJWTSRM-UHFFFAOYSA-N 4-iodobenzonitrile Chemical compound IC1=CC=C(C#N)C=C1 XOKDXPVXJWTSRM-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QJNLUNBGDFUULX-UHFFFAOYSA-N 4-n,4-n'-dimethyl-3h-pyridine-4,4-diamine Chemical compound CNC1(NC)CC=NC=C1 QJNLUNBGDFUULX-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZQDQJNYKEHPNHY-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-1-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3C=C(Cl)C=C(Cl)C=3)C=C2C=C1C(O)=O ZQDQJNYKEHPNHY-UHFFFAOYSA-N 0.000 description 1
- SKDNCVOZDSKBMA-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(C=3C=CC(Cl)=CC=3)C=C2C=C1C(O)=O SKDNCVOZDSKBMA-UHFFFAOYSA-N 0.000 description 1
- HQZICRQQIFTIHH-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-(3-nitro-4-propan-2-yloxyphenyl)indole-2-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC=C1N1C2=CC=C(C=3C=CC(=CC=3)C(C)(C)C)C=C2C=C1C(O)=O HQZICRQQIFTIHH-UHFFFAOYSA-N 0.000 description 1
- CFSGRWCLQNCELW-UHFFFAOYSA-N 5-(4-tert-butylphenyl)-1-[4-(2-carboxyethenyl)phenyl]indole-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(N(C(=C2)C(O)=O)C=3C=CC(C=CC(O)=O)=CC=3)C2=C1 CFSGRWCLQNCELW-UHFFFAOYSA-N 0.000 description 1
- VTUDATOSQGYWML-UHFFFAOYSA-N 5-bromo-1h-pyrimidin-2-one Chemical compound OC1=NC=C(Br)C=N1 VTUDATOSQGYWML-UHFFFAOYSA-N 0.000 description 1
- ZCTNUTZJUDVPOD-UHFFFAOYSA-N 5-bromo-2-cyclopentyloxypyridine Chemical compound N1=CC(Br)=CC=C1OC1CCCC1 ZCTNUTZJUDVPOD-UHFFFAOYSA-N 0.000 description 1
- AEDSMUUEBQNEAA-UHFFFAOYSA-N 5-bromo-2-piperidin-1-ylpyridine Chemical compound N1=CC(Br)=CC=C1N1CCCCC1 AEDSMUUEBQNEAA-UHFFFAOYSA-N 0.000 description 1
- KYTYURKMIVIKRA-UHFFFAOYSA-N 5-bromo-5-cyclopropyloxycyclohexa-1,3-diene Chemical compound C1CC1OC1(Br)CC=CC=C1 KYTYURKMIVIKRA-UHFFFAOYSA-N 0.000 description 1
- UHRHPPKWXSNZLR-UHFFFAOYSA-N 5-bromopyrimidin-2-amine Chemical compound NC1=NC=C(Br)C=N1 UHRHPPKWXSNZLR-UHFFFAOYSA-N 0.000 description 1
- SZFUWUOHDRMCKD-UHFFFAOYSA-N 5-chloro-1h-pyridin-2-one Chemical compound OC1=CC=C(Cl)C=N1 SZFUWUOHDRMCKD-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- VFNFKMFTFFMIRW-UHFFFAOYSA-N 5-iodo-1h-indole-2-carboxylic acid Chemical compound IC1=CC=C2NC(C(=O)O)=CC2=C1 VFNFKMFTFFMIRW-UHFFFAOYSA-N 0.000 description 1
- XTHKRYHULUJQHN-UHFFFAOYSA-N 6-bromopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1 XTHKRYHULUJQHN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FOZCPWOWORVRCT-UHFFFAOYSA-N BrC1=CC=C(C=C1)O.BrC1=CC=C(C=C1)OCC(C)C Chemical compound BrC1=CC=C(C=C1)O.BrC1=CC=C(C=C1)OCC(C)C FOZCPWOWORVRCT-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PAVZCPQXWXJEGM-UHFFFAOYSA-N C1=CC([B])=CC=C1OC1CCCC1 Chemical compound C1=CC([B])=CC=C1OC1CCCC1 PAVZCPQXWXJEGM-UHFFFAOYSA-N 0.000 description 1
- MZZKGWVBQFQUNK-UHFFFAOYSA-N CC(C)OC1=NC=C(C=C1)C2=CC3=C(C=C2)NC(=C3)C(=O)O Chemical compound CC(C)OC1=NC=C(C=C1)C2=CC3=C(C=C2)NC(=C3)C(=O)O MZZKGWVBQFQUNK-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000006147 Japp-Klingemann synthesis reaction Methods 0.000 description 1
- 102100023758 Leukotriene C4 synthase Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- LDQLYYLVRZNFHS-UHFFFAOYSA-N OS(=O)(=O)I(Cl)Br Chemical group OS(=O)(=O)I(Cl)Br LDQLYYLVRZNFHS-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108050003514 Prostaglandin E synthase 2 Proteins 0.000 description 1
- 102100030484 Prostaglandin E synthase 2 Human genes 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- AIJCNTOYZPKURP-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1OC(F)(F)F AIJCNTOYZPKURP-UHFFFAOYSA-N 0.000 description 1
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 1
- LQZUPTNBDDHDPV-UHFFFAOYSA-N [3-chloro-1-(4-cyclopentyloxyphenyl)-2-ethoxycarbonylindol-5-yl]boronic acid Chemical compound CCOC(=O)C1=C(Cl)C2=CC(B(O)O)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 LQZUPTNBDDHDPV-UHFFFAOYSA-N 0.000 description 1
- SFDALWLXKHKMEE-UHFFFAOYSA-N [3-chloro-2-ethoxycarbonyl-1-(4-propan-2-yloxyphenyl)indol-5-yl]boronic acid Chemical compound CCOC(=O)C1=C(Cl)C2=CC(B(O)O)=CC=C2N1C1=CC=C(OC(C)C)C=C1 SFDALWLXKHKMEE-UHFFFAOYSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- DXQXWMYUGOTNGJ-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boron Chemical compound [B]C1=CC=C(C(F)(F)F)C=C1 DXQXWMYUGOTNGJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 206010007604 cardiac sarcoidosis Diseases 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- PJGJQVRXEUVAFT-UHFFFAOYSA-N chloroiodomethane Chemical compound ClCI PJGJQVRXEUVAFT-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- DJPYDPFHXZCOJL-UHFFFAOYSA-N cyclobutylmethoxybenzene Chemical compound C1CCC1COC1=CC=CC=C1 DJPYDPFHXZCOJL-UHFFFAOYSA-N 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- LMAJREOZDVKQCZ-UHFFFAOYSA-N ditert-butyl-[2-(2-ditert-butylphosphanylphenyl)phenyl]phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C LMAJREOZDVKQCZ-UHFFFAOYSA-N 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- SBQXEMOPQYACDX-UHFFFAOYSA-N ethyl 1-(4-cyclopentyloxyphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-2-carboxylate Chemical class CCOC(=O)C1=CC2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 SBQXEMOPQYACDX-UHFFFAOYSA-N 0.000 description 1
- PDSHLIRQKBIJKF-UHFFFAOYSA-N ethyl 1-(4-cyclopropyloxyphenyl)-5-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3N=CC(=CC=3)C(F)(F)F)=CC=C2N1C(C=C1)=CC=C1OC1CC1 PDSHLIRQKBIJKF-UHFFFAOYSA-N 0.000 description 1
- KHWLLXPMLUQULT-UHFFFAOYSA-N ethyl 1-(4-propan-2-yloxyphenyl)-5-(6-propan-2-yloxypyridin-3-yl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3C=NC(OC(C)C)=CC=3)=CC=C2N1C1=CC=C(OC(C)C)C=C1 KHWLLXPMLUQULT-UHFFFAOYSA-N 0.000 description 1
- DRJWEOYWZOGNQU-UHFFFAOYSA-N ethyl 3-bromo-1h-indole-2-carboxylate Chemical compound C1=CC=C2C(Br)=C(C(=O)OCC)NC2=C1 DRJWEOYWZOGNQU-UHFFFAOYSA-N 0.000 description 1
- DIVSRHSHSUIBKE-UHFFFAOYSA-N ethyl 3-chloro-1-(4-cyclopentyloxyphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-2-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 DIVSRHSHSUIBKE-UHFFFAOYSA-N 0.000 description 1
- UMSIJJPAYRKSSA-UHFFFAOYSA-N ethyl 4-amino-1,5-bis(4-propan-2-yloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=C(N)C(C=3C=CC(OC(C)C)=CC=3)=CC=C2N1C1=CC=C(OC(C)C)C=C1 UMSIJJPAYRKSSA-UHFFFAOYSA-N 0.000 description 1
- UYLFCAGPBQCFNU-UHFFFAOYSA-N ethyl 5-(3,5-dichlorophenyl)-1h-indole-2-carboxylate Chemical class C=1C=C2NC(C(=O)OCC)=CC2=CC=1C1=CC(Cl)=CC(Cl)=C1 UYLFCAGPBQCFNU-UHFFFAOYSA-N 0.000 description 1
- UZXCDTWNNHTYEB-UHFFFAOYSA-N ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate ethyl 5-[5-(trifluoromethyl)pyridin-2-yl]-1H-indole-2-carboxylate Chemical compound C(C)OC(=O)C=1NC2=CC=C(C=C2C1)B1OC(C(O1)(C)C)(C)C.C(C)OC(=O)C=1NC2=CC=C(C=C2C1)C1=NC=C(C=C1)C(F)(F)F UZXCDTWNNHTYEB-UHFFFAOYSA-N 0.000 description 1
- BFNARGGMOBETDJ-UHFFFAOYSA-N ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1B1OC(C)(C)C(C)(C)O1 BFNARGGMOBETDJ-UHFFFAOYSA-N 0.000 description 1
- AERMNRJIRODQLN-UHFFFAOYSA-N ethyl 5-(4-cyanophenyl)-1-(4-cyclopropyloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3C=CC(=CC=3)C#N)=CC=C2N1C(C=C1)=CC=C1OC1CC1 AERMNRJIRODQLN-UHFFFAOYSA-N 0.000 description 1
- WFDDYKDUQCBCMD-UHFFFAOYSA-N ethyl 5-(4-cyanophenyl)-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C1=CC=C(C#N)C=C1 WFDDYKDUQCBCMD-UHFFFAOYSA-N 0.000 description 1
- LMSMXAUTPXQGPV-UHFFFAOYSA-N ethyl 5-(4-propan-2-yloxyphenyl)-1-(6-propan-2-yloxypyridin-3-yl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3C=CC(OC(C)C)=CC=3)=CC=C2N1C1=CC=C(OC(C)C)N=C1 LMSMXAUTPXQGPV-UHFFFAOYSA-N 0.000 description 1
- ZOJRPINTNKCFKF-UHFFFAOYSA-N ethyl 5-(4-tert-butylphenyl)-1-(4-propan-2-yloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3C=CC(=CC=3)C(C)(C)C)=CC=C2N1C1=CC=C(OC(C)C)C=C1 ZOJRPINTNKCFKF-UHFFFAOYSA-N 0.000 description 1
- MTIQVGRYIBBIJK-UHFFFAOYSA-N ethyl 5-(5-bromopyrimidin-2-yl)-1-(4-cyclopentyloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(C=3N=CC(Br)=CN=3)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 MTIQVGRYIBBIJK-UHFFFAOYSA-N 0.000 description 1
- HYDQXHJKMMREOD-UHFFFAOYSA-N ethyl 5-(6-propan-2-yloxypyridin-3-yl)-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C1=CC=C(OC(C)C)N=C1 HYDQXHJKMMREOD-UHFFFAOYSA-N 0.000 description 1
- ORULTWNTACVPNA-UHFFFAOYSA-N ethyl 5-bromo-1-(4-cyclopentyloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(Br)=CC=C2N1C(C=C1)=CC=C1OC1CCCC1 ORULTWNTACVPNA-UHFFFAOYSA-N 0.000 description 1
- AFAYUSKPSLSBGT-UHFFFAOYSA-N ethyl 5-bromo-1-(4-propan-2-yloxyphenyl)indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(Br)=CC=C2N1C1=CC=C(OC(C)C)C=C1 AFAYUSKPSLSBGT-UHFFFAOYSA-N 0.000 description 1
- CMGCJTFXYGLJBM-UHFFFAOYSA-N ethyl 5-bromo-3-chloro-1h-indole-2-carboxylate Chemical compound C1=C(Br)C=C2C(Cl)=C(C(=O)OCC)NC2=C1 CMGCJTFXYGLJBM-UHFFFAOYSA-N 0.000 description 1
- FVMZWWFKRMBNSZ-UHFFFAOYSA-N ethyl 6-bromo-1h-indole-2-carboxylate Chemical compound C1=C(Br)C=C2NC(C(=O)OCC)=CC2=C1 FVMZWWFKRMBNSZ-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 108010087711 leukotriene-C4 synthase Proteins 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- MJBIEVZJGGUYSN-UHFFFAOYSA-N methyl 2-(4-bromophenoxy)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=C(Br)C=C1 MJBIEVZJGGUYSN-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- YGDICLRMNDWZAK-UHFFFAOYSA-N quinolin-3-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CN=C21 YGDICLRMNDWZAK-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- MMYLGRKCTRDDIW-UHFFFAOYSA-M sodium;3-chloro-5-(4-cyclohexylphenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]indole-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1=C(Cl)C2=CC(C=3C=CC(=CC=3)C3CCCCC3)=CC=C2N1C1=CC=C(C(F)(F)F)C=N1 MMYLGRKCTRDDIW-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58040104P | 2004-06-18 | 2004-06-18 | |
| PCT/GB2005/002391 WO2005123673A1 (en) | 2004-06-18 | 2005-06-17 | Indoles useful in the treatment of inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502669A true JP2008502669A (ja) | 2008-01-31 |
| JP2008502669A5 JP2008502669A5 (enExample) | 2008-08-07 |
Family
ID=34956079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516043A Withdrawn JP2008502669A (ja) | 2004-06-18 | 2005-06-17 | 炎症の治療に有用なインドール類 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7705023B2 (enExample) |
| EP (1) | EP1778632B1 (enExample) |
| JP (1) | JP2008502669A (enExample) |
| KR (1) | KR20070028553A (enExample) |
| CN (1) | CN101006053A (enExample) |
| AT (1) | ATE405549T1 (enExample) |
| AU (1) | AU2005254782A1 (enExample) |
| BR (1) | BRPI0512252A (enExample) |
| CA (1) | CA2570363A1 (enExample) |
| DE (1) | DE602005009209D1 (enExample) |
| ES (1) | ES2315877T3 (enExample) |
| IL (1) | IL179728A0 (enExample) |
| MX (1) | MXPA06014535A (enExample) |
| RU (1) | RU2007101705A (enExample) |
| WO (1) | WO2005123673A1 (enExample) |
| ZA (1) | ZA200610357B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080146616A1 (en) * | 2004-06-18 | 2008-06-19 | Kristofer Olofsson | Indoles Useful in the Treatment of Inflammation |
| KR20070028553A (ko) | 2004-06-18 | 2007-03-12 | 바이올리폭스 에이비 | 염증 치료에 유용한 인돌 |
| WO2006077366A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| EP1841736A1 (en) * | 2005-01-19 | 2007-10-10 | Biolipox AB | Indoles useful in the treatment of inflammation |
| AR056690A1 (es) * | 2005-10-14 | 2007-10-17 | Athersys Inc | Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc |
| UA95788C2 (en) | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| MX2008015662A (es) | 2006-06-08 | 2009-01-12 | Lilly Co Eli | Nuevos receptores antagonistas de la hormona concentradora de melanina (mch). |
| WO2008009924A2 (en) * | 2006-07-18 | 2008-01-24 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| MX2009011210A (es) * | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| CN102186845B (zh) | 2008-10-17 | 2016-09-07 | 阿卡制药有限公司 | S1p受体调节剂以及它们的用途 |
| EP2344446A4 (en) | 2008-10-17 | 2012-04-04 | Akaal Pharma Pty Ltd | S1P RECEPTOR MODULATORS |
| US20120029016A1 (en) | 2008-12-30 | 2012-02-02 | Biolipox Ab | Indoles Useful in the Treatment of Inflammation |
| WO2010127152A2 (en) * | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| CN108929203A (zh) * | 2018-08-14 | 2018-12-04 | 重庆市化工研究院 | 一种芳香族乙烯基醚及其合成方法和应用 |
| WO2021040393A1 (ko) * | 2019-08-26 | 2021-03-04 | 국제약품 주식회사 | 인돌 카복사미드 유도체 및 그를 포함하는 약제학적 조성물 |
| CN113233980B (zh) * | 2021-04-02 | 2022-04-05 | 台州学院 | 一种β-氯代酸酯及α，β-不饱和酸酯类化合物的合成方法 |
| CN118121595B (zh) * | 2024-05-06 | 2024-08-16 | 广州市朝利良生物科技有限公司 | 化合物eh-p005j在制备促伤口愈合药物中的用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU85435A1 (fr) | 1984-06-27 | 1986-01-24 | Amylum Graanderivaten Raff | Procede de preparation d'un carboxymethylamidon,carboxymethylamidon ainsi obtenu et produit de lavage contenant un tel carboxymethylamidon |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| US5081138A (en) | 1986-12-17 | 1992-01-14 | Merck Frosst Canada, Inc. | 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith |
| NZ222878A (en) | 1986-12-17 | 1991-02-26 | Merck Frosst Canada Inc | 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions |
| US4960786A (en) | 1989-04-24 | 1990-10-02 | Merrell Dow Pharmaceuticals Inc. | Excitatory amino acid antagonists |
| PT95899A (pt) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| US5081145A (en) | 1990-02-01 | 1992-01-14 | Merck Frosst Canada, Inc. | Indole-2-alkanoic acids compositions of and anti allergic use thereof |
| US5374615A (en) | 1990-10-31 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives |
| PH31175A (en) | 1990-10-31 | 1998-03-20 | Squibb & Sons Inc | Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives. |
| US5189054A (en) | 1990-11-02 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | 3-amidoindolyl derivatives and pharmaceutical compositions thereof |
| AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
| CA2079374C (en) | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| US5389650A (en) | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| US5234923A (en) | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
| HUT70954A (en) | 1992-04-03 | 1995-11-28 | Upjohn Co | Bicyclic-heterocyclic amines containing nitrogen heteroatoms |
| US5294722A (en) | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
| US5236916A (en) | 1992-05-26 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Oxadiazinone substituted indole and benzimidazole derivatives |
| TW229140B (enExample) | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
| US5334719A (en) | 1992-06-17 | 1994-08-02 | Merck Frosst Canada, Inc. | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis |
| ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP0804416A1 (en) | 1994-07-27 | 1997-11-05 | Sankyo Company Limited | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors |
| JPH10510538A (ja) | 1994-12-13 | 1998-10-13 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| AU717430B2 (en) | 1996-08-26 | 2000-03-23 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| US5910622A (en) | 1996-10-29 | 1999-06-08 | Dcv, Inc. | Method for treating fibrous cellulosic materials |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| DE19742263A1 (de) | 1997-09-25 | 1999-04-01 | Asta Medica Ag | Neue spezifische Immunophilin-Liganden als Antiasthmatika, Antiallergika, Antirheumatika, Immunsuppressiva, Antipsoriatika, Neuroprotektiva |
| HU227568B1 (en) | 1997-12-24 | 2011-08-29 | Sanofi Aventis Deutschland | Indole derivatives, as inhibitors os factor xa |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| SK12742000A3 (sk) | 1998-02-25 | 2001-05-10 | Genetics Institute, Inc. | Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie |
| PL343007A1 (en) | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
| EA200000873A1 (ru) | 1998-02-25 | 2001-04-23 | Дженетикс Инститьют, Инк. | Ингибиторы фосфолипазы a |
| WO1999043434A1 (en) | 1998-02-27 | 1999-09-02 | Ventana Medical Systems, Inc. | System and method of aspirating and dispensing reagent |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| EP1194135A2 (en) | 1999-06-29 | 2002-04-10 | The UAB Research Foundation | Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| JP2001069477A (ja) * | 1999-08-31 | 2001-03-16 | Sony Corp | 番組提供システム及び番組提供方法 |
| JP2003525217A (ja) | 1999-10-22 | 2003-08-26 | メルク エンド カムパニー インコーポレーテッド | 肥満治療用薬剤 |
| AU7962200A (en) | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
| US6353007B1 (en) | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| PL366068A1 (en) | 2000-10-10 | 2005-01-24 | Smithkline Beecham Corporation | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents |
| KR20040047862A (ko) | 2001-09-27 | 2004-06-05 | 에프. 호프만-라 로슈 아게 | Ｃｏｘ ⅱ 억제제로서의 인돌 유도체 |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| AU2002357003A1 (en) | 2001-12-28 | 2003-07-24 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
| US7226938B2 (en) | 2002-09-06 | 2007-06-05 | Janssen Pharmaceutica, N.V. | Heterocyclic compounds |
| EP1646624A1 (en) | 2003-07-09 | 2006-04-19 | Biolipox AB | Indoles useful in the treatment of inflammation |
| KR20070028553A (ko) | 2004-06-18 | 2007-03-12 | 바이올리폭스 에이비 | 염증 치료에 유용한 인돌 |
| KR20070029809A (ko) | 2004-06-18 | 2007-03-14 | 바이올리폭스 에이비 | 염증치료에 유용한 인돌 |
| JP2008527027A (ja) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| EP2143431A1 (en) | 2005-05-17 | 2010-01-13 | Santen Pharmaceutical Co., Ltd. | Protective agent for neurocyte comprising amidino derivative as active ingredient |
-
2005
- 2005-06-17 KR KR1020077001307A patent/KR20070028553A/ko not_active Withdrawn
- 2005-06-17 BR BRPI0512252-0A patent/BRPI0512252A/pt not_active IP Right Cessation
- 2005-06-17 AT AT05751812T patent/ATE405549T1/de not_active IP Right Cessation
- 2005-06-17 EP EP05751812A patent/EP1778632B1/en not_active Expired - Lifetime
- 2005-06-17 AU AU2005254782A patent/AU2005254782A1/en not_active Abandoned
- 2005-06-17 MX MXPA06014535A patent/MXPA06014535A/es unknown
- 2005-06-17 US US11/629,624 patent/US7705023B2/en not_active Expired - Fee Related
- 2005-06-17 CN CNA2005800277808A patent/CN101006053A/zh active Pending
- 2005-06-17 ZA ZA200610357A patent/ZA200610357B/en unknown
- 2005-06-17 ES ES05751812T patent/ES2315877T3/es not_active Expired - Lifetime
- 2005-06-17 WO PCT/GB2005/002391 patent/WO2005123673A1/en not_active Ceased
- 2005-06-17 RU RU2007101705/04A patent/RU2007101705A/ru not_active Application Discontinuation
- 2005-06-17 DE DE602005009209T patent/DE602005009209D1/de not_active Expired - Lifetime
- 2005-06-17 CA CA002570363A patent/CA2570363A1/en not_active Abandoned
- 2005-06-17 JP JP2007516043A patent/JP2008502669A/ja not_active Withdrawn
-
2006
- 2006-11-30 IL IL179728A patent/IL179728A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06014535A (es) | 2007-06-05 |
| KR20070028553A (ko) | 2007-03-12 |
| RU2007101705A (ru) | 2008-07-27 |
| EP1778632A1 (en) | 2007-05-02 |
| BRPI0512252A (pt) | 2008-02-19 |
| ZA200610357B (en) | 2008-02-27 |
| EP1778632B1 (en) | 2008-08-20 |
| ATE405549T1 (de) | 2008-09-15 |
| WO2005123673A1 (en) | 2005-12-29 |
| CA2570363A1 (en) | 2005-12-29 |
| ES2315877T3 (es) | 2009-04-01 |
| US20070287715A1 (en) | 2007-12-13 |
| DE602005009209D1 (de) | 2008-10-02 |
| IL179728A0 (en) | 2007-05-15 |
| AU2005254782A1 (en) | 2005-12-29 |
| US7705023B2 (en) | 2010-04-27 |
| CN101006053A (zh) | 2007-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1841735B1 (en) | Indoles useful in the treatment of inflammation | |
| US7705023B2 (en) | Indoles useful in the treatment of inflammation | |
| JP2008527027A (ja) | 炎症の治療に有用なインドール類 | |
| JP2008527030A (ja) | 炎症の治療に有用なインドール類 | |
| US20090042949A1 (en) | Indoles Useful in the Treatment of Inflammation | |
| JP2008502670A (ja) | 炎症の治療に有用なインドール類 | |
| JP2008527031A (ja) | 炎症の治療に有用なピロロピリジン誘導体 | |
| JP2008527032A (ja) | 炎症の治療に有用なチエノピロール | |
| JP2007516203A (ja) | 炎症の治療に有用なインドール類 | |
| EP1765775B1 (en) | Indoles useful in the treatment of inflammation | |
| US20060160879A1 (en) | Indoles useful in the treatment of inflammation | |
| HK1105975B (en) | Indoles useful in the treatment of inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080612 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080612 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20101201 |